Predictors of short-term success of antiretroviral therapy in HIV infection

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 1, 2006, Pages 147-153

  Oette, Mark ^a   Kroidl, Arne ^a   Göbels, Klaus ^a   Stabbert, Antje ^a   Menge, Marion ^a   Sagir, Abdurrahman ^a   Kuschak, Dieter ^b   O'Hanley, Tara ^a   Bode, Johannes G ^a   Häussinger, Dieter ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b Medical Laboratories   (Germany)

Author keywords

Adherence; HAART; Quality of life; Social; TDM

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; EFAVIRENZ; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG TREATMENT FAILURE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PREDICTION; QUALITY OF LIFE; QUESTIONNAIRE; RISK ASSESSMENT; SELF REPORT; SHORT COURSE THERAPY; SOCIAL ASPECT; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33748082995     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl189     Document Type: Article

References (45)

1. Egger M, May M, Chene G et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 2002; 360: 119-29.
2. Bartlett JA, DeMasi R, Quinn J et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001; 15: 1369-77.
3. Boffito M, Acosta E, Burger D et al. Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy. Antivir Ther 2005; 10: 375-92.
4. Clevenbergh P, Mouly S, Sellier P et al. Improving HIV infection management using antiretroviral plasma drug levels monitoring: A clinician's point of view. Curr HIV Res 2004; 2: 309-21.
5. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001; 344: 984-96.
6. Rendón AL, Núnez M, Jiménez-Nácher I et al. Clinical benefit of interventions driven by therapeutic drug monitoring. HIV Med 2005; 6: 360-5.
7. Aarnoutse RE, Schapiro JM, Boucher CA et al. Therapeutic drug monitoring: An aid to optimising response to antiretroviral drugs? Drugs 2003; 63: 741-53.
8. Burger DM, Hoetelmans RM, Hugen PW et al. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antivir Ther 1998; 3: 215-20.
9. Powderly WG, Saag MS, Chapman S et al. Predictors of optimal virological response to potent antiretroviral therapy. AIDS 1999; 13: 1873-80.
10. Touw DJ, Neef C, Thomson AH et al. Cost-effectiveness of therapeutic drug monitoring: A systematic review. Ther Drug Monit 2005; 27: 10-7.
11. Mannheimer S, Friedland G, Matts J et al. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 2002; 34: 1115-21.
12. Bangsberg DR, Hecht FM, Charlebois ED et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14: 357-66.
13. Duong M, Piroth L, Peytavin G et al. Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: Relationship to virologic response. Clin Infect Dis 2001; 33: 386-92.
14. Duval X, Mentre F, Lamotte C et al. Indinavir plasma concentration and adherence score are codeterminant of early virologic response in HIV-infected patients of the APROCO Cohort. Ther Drug Monit 2005; 27: 63-70.
15. Paterson DL, Swindells S, Mohr J et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30.
16. Raboud JM, Harris M, Rae S et al. Impact of adherence on duration of virological suppression among patients receiving combination antiretroviral therapy. HIV Med 2002; 3: 118-24.
17. Bangsberg DR, Perry S, Charlebois ED et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001; 15: 1181-3.
18. Murri R, Ammassari A, Gallicano K et al. Patient-reported nonadherence to HAART is related to protease inhibitor levels. J Acquir Immune Defic Syndr 2000; 24: 123-8.
19. Ammassari A, Trotta MP, Murri R et al. Correlates and predictors of adherence to highly active antiretroviral therapy: Overview of published literature. J Acquir Immune Defic Syndr 2002; 31 Suppl 3: S123-7.
20. Goujard C, Bernard N, Sohier N et al. Impact of a patient education program on adherence to HIV medication: A randomized clinical trial. J Acquir Immune Defic Syndr 2003; 34: 191-4.
21. Le Moing V, Chene G, Carrieri MP et al. Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors. J Acquir Immune Defic Syndr 2001; 27: 372-6.
22. Dray-Spira R, Lert F. Social health inequalities during the course of chronic HIV disease in the era of highly active antiretroviral therapy. AIDS 2003; 17: 283-90.
23. Gordillo V, del Amo J, Soriano V et al. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999; 13: 1763-9.
24. McFarland W, Chen S, Hsu L et al. Low socioeconomic status is associated with a higher rate of death in the era of highly active antiretroviral therapy, San Francisco. J Acquir Immune Defic Syndr 2003; 33: 96-103.
25. Wood E, Montaner JS, Chan K et al. Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996. AIDS 2002; 16: 2065-72.
26. Antinori A, Cozzi-Lepri A, Ammassari A et al. Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART. Antivir Ther 2004; 9: 291-6.
27. Reynolds NR, Testa MA, Marc LG et al. Factors influencing medication adherence beliefs and self-efficacy in persons naive to antiretroviral therapy: A multicenter, cross-sectional study. AIDS Behav 2004; 8: 141-50.
28. Alexander CS, Asselin JJ, Ting LS et al. Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease. J Infect Dis 2003; 188: 541-8.
29. Liechty CA, Alexander CS, Harrigan PR et al. Are untimed antiretroviral drug levels useful predictors of adherence behavior? AIDS 2004; 18: 127-9.
30. Kuschak D, Mauss S, Schmutz G et al. Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir (1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir (3) in human plasma by gradient HPLC. Clin Lab 2001; 47: 471-7.
31. Wachtel T, Piette J, Mor V et al. Quality of life in persons with human immunodeficiency virus infection: Measurement by the Medical Outcomes Study instrument. Ann Intern Med 1992; 116: 129-37.
32. Wu AW, Hays RD, Kelly S et al. Applications of the Medical Outcomes Study health-related quality of life measures in HIV/AIDS. Qual Life Res 1997; 6: 531-54.
33. Nieuwkerk PT, Sprangers MA, Burger DM et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med 2001; 161: 1962-8.
34. Lucas GM, Wu AW, Cheever LW. Adherence to antiretroviral therapy: An update of current concepts. Curr HIV/AIDS Rep 2004; 1: 172-80.
35. Le Moing V, Chene G, Carrieri MP et al. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 2002; 16: 21-9.
36. Back DJ, Khoo SH, Gibbons SE et al. Therapeutic drug monitoring of antiretrovirals in human immunodeficiency virus infection. Ther Drug Monit 2000; 22: 122-6.
37. Castagna A, Gianotti N, Galli L et al. The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ ritonavir-containing regimen. Antivir Ther 2004; 9: 537-43.
38. Yasuda JM, Miller C, Currier JS et al. The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patients. Antivir Ther 2004; 9: 753-61.
39. Alcoba M, Cuevas MJ, Perez-Simon MR et al. Assessment of adherence to triple antiretroviral treatment including indinavir: Role of the determination of plasma levels of indinavir. J Acquir Immune Defic Syndr 2003; 33: 253-8.
40. Duran S, Peytavin G, Carrieri P et al. The detection of non-adherence by self-administered questionnaires can be optimized by protease inhibitor plasma concentration determination. AIDS 2003; 17: 1096-9.
41. Hugen PW, Burger DM, Aarnoutse RE et al. Therapeutic drug monitoring of HIV-protease inhibitors to assess noncompliance. Ther Drug Monit 2002; 24: 579-87.
42. Haubrich RH, Little SJ, Currier JS et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS 1999; 13: 1099-107.
43. Carrieri P, Cailleton V, Le Moing V et al. The dynamic of adherence to highly active antiretroviral therapy: Results from the French National APROCO cohort. J Acquir Immune Defic Syndr 2001; 28: 232-9.
44. Kroidl A, Menge M, Oette M et al. Evaluation of different strategies of therapeutic drug monitoring (TDM) for response to antiretroviral treatment and virologic outcome in HIV. 10th European AIDS Conference, Dublin, 2005. Abstract PE4.2/9.
45. Kroidl A, Stabbert A, Oette M et al. Therapeutic drug monitoring in unscheduled plasma samples predict therapy outcome in HIV-positive patients. Eur J Med Res 2005; 10 Suppl 2: 27, Abstract V9.